PTC Therapeutics
From Wikipedia, the free encyclopedia
Coordinates: 40°33′03″N 74°25′23″W / 40.550722°N 74.4230711°W PTC Therapeutics is a pharmaceutical company. It is headquartered in South Plainfield, New Jersey.
They are the company responsible for the development of PTC124.[1]
As of September 2009, PTC has entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system disease targets. Roche said use of PTC's GEMS technology for the identification of small molecules "will enable Roche to address important disease mechanisms that were intractable with conventional approaches." [2]
[edit] References
- ^ Hamed SA (2006). "Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy". IDrugs : the investigational drugs journal 9 (11): 783–9. PMID 17096300.
- ^ http://www.firstwordplus.com/Fws.do?articleid=A2B13ACB78294EB0A27EE127D8339BF3
[edit] Further reading
- Schneider, Ilene (2009). "Firm Aims to Regulate RNA in Rare Diseases". Genetic Engineering & Biotechnology News 29 (8): 14. http://www.genengnews.com/articles/chitem.aspx?aid=2869. Retrieved 2009-04-25
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
